Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
ACADIA Pharmaceuticals (ACAD) has provided an announcement.
Acadia Pharmaceuticals Inc. successfully conducted its 2024 Annual Meeting on May 29, where stockholders elected three Class II directors to its Board, set to serve until the 2027 Annual Meeting. Additionally, the compensation of the company’s named executive officers was approved, as was the Plan presented during the meeting. Moreover, Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Each decision was made with an overwhelming majority of votes in favor.
See more data about ACAD stock on TipRanks’ Stock Analysis page.
